Thiamine precursors, the most studied being benfotiamine (BFT), have protective effects in mouse models of neurodegenerative diseases. BFT decreased oxidative stress and inflammation, two major characteristics of neurodegenerative diseases, in a neuroblastoma cell line (Neuro2a) and an immortalized brain microglial cell line (BV2). Here, we tested the potential antioxidant and anti-inflammatory effects of the hitherto unexplored derivative O,S-dibenzoylthiamine (DBT) in these two cell lines. We show that DBT protects Neuro2a cells against paraquat (PQ) toxicity by counteracting oxidative stress at low concentrations and increases the synthesis of reduced glutathione and NADPH in a Nrf2-independent manner. In BV2 cells activated by lipopolysaccharides (LPS), DBT significantly decreased inflammation by suppressing translocation of NF-κB to the nucleus. Our results also demonstrate the superiority of DBT over thiamine and other thiamine precursors, including BFT, in all of the in vitro models. Finally, we show that the chronic administration of DBT arrested motor dysfunction in FUS transgenic mice, a model of amyotrophic lateral sclerosis, and it reduced depressive-like behavior in a mouse model of ultrasound-induced stress in which it normalized oxidative stress marker levels in the brain. Together, our data suggest that DBT may have therapeutic potential for brain pathology associated with oxidative stress and inflammation by novel, coenzyme-independent mechanisms.
Genome-wide screening approaches identified the cell adhesion molecule Cadherin-13 (CDH13) as a risk factor for neurodevelopmental disorders, nevertheless the contribution of CDH13 to the disease mechanism remains obscure. CDH13 is involved in neurite outgrowth and axon guidance during early brain development and we previously provided evidence that constitutive CDH13 deficiency influences the formation of the raphe serotonin (5-HT) system by modifying neuron-radial glia interaction. Here, we dissect the specific impact of CDH13 on 5-HT system development and function using a 5-HT neuron-specific Cdh13 knockout mouse model (conditional Cdh13 knockout, Cdh13 cKO). Our results show that exclusive inactivation of CDH13 in 5-HT neurons selectively increases 5-HT neuron density in the embryonic dorsal raphe, with persistence into adulthood, and serotonergic innervation of the developing prefrontal cortex. At the behavioral level, adult Cdh13 cKO mice display delayed acquisition of several learning tasks and a subtle impulsive-like phenotype, with decreased latency in a sociability paradigm alongside with deficits in visuospatial memory. Anxiety-related traits were not observed in Cdh13 cKO mice. Our findings further support the critical role of CDH13 in the development of dorsal raphe 5-HT circuitries, a mechanism that may underlie specific clinical features observed in neurodevelopmental disorders.
Fetal growth restriction (FGR) is a significant pregnancy complication strongly associated with neurodevelopmental deficits in infants. Effective treatments to support brain development are currently lacking. Detailed characterization of structural and functional brain abnormalities caused by FGR can aid the development of targeted therapies. This study aimed to comprehensively characterise brain development at anatomical, cellular and functional levels in a rat model of placental‐insufficiency‐induced FGR, using the reduced uterine perfusion pressure (RUPP) method. Pregnant Sprague–Dawley rats underwent partial occlusion of the lower abdominal aorta and bilateral ovarian arteries at embryonic day 14. Sham‐operated dams served as controls. Offspring were weighed until postnatal day (P)66–67 and underwent behavioural testing; a subset of animals was assessed by histology and MRI at P20. Offspring born from RUPP dams showed an FGR phenotype characterised by decreased body weight without catch‐up growth. RUPP pups exhibited reduced brain weight and volume, cortical thinning and altered cortical organization. Additionally, aberrant myelination, and increased immune reactivity and morphological changes of microglia were observed in RUPP pups. These neurological impairments were accompanied by delayed eye opening, increased number of ultrasonic vocalizations, and motor deficits that persisted into adulthood. This is the first study to demonstrate that RUPP in rats leads to FGR‐induced neurological impairments and lasting behavioural abnormalities in the offspring, highlighting the long‐term vulnerability of FGR rather than its being an acute perinatal event. This model is valuable for advancing understanding of brain injury in affected infants and for developing novel therapies aimed at improving neurodevelopmental outcomes. image Key points: Fetal growth restriction (FGR) is a common pregnancy complication linked to long‐term brain and neurodevelopmental deficits in infants. The reduced uterine perfusion pressure (RUPP) in rats mimics FGR in the offspring, causing FGR‐related brain injury and behavioural abnormalities. RUPP pups show reduced body and brain weight, thinner cerebral cortex, abnormal distribution of key interneurons, aberrant myelination, disrupted oligodendrocyte maturation and signs of neuroinflammation. RUPP offspring also display neurodevelopmental delays and motor deficits that persist into adulthood, comparable to what is seen in FGR infants. The RUPP model is valuable for studying how FGR affects the brain and for developing targeted therapeutic approaches to improve long‐term outcomes in affected infants.
18 August 2026 in Stem Cells Translational Medicine
Fetal growth restriction (FGR), a condition in which a fetus fails to reach its full growth potential, affects approximately 30 million infants worldwide each year and increases the risk of long-term neurodevelopmental deficits. Currently, no effective therapies exist to mitigate FGR-induced neurological impairments. Mesenchymal stem cells (MSCs) have emerged as a promising neuroregenerative therapeutic approach. Here, we used the reduced uterine perfusion pressure (RUPP) rat model of chronic placental hypoperfusion-induced FGR. We explored, for the first time, intranasal MSC administration in the early postnatal period in growth-restricted offspring as a minimally invasive and clinically feasible cell delivery approach. RUPP pups received human Wharton’s jelly-derived MSCs or vehicle intranasally at postnatal day 5 (P5) or P10, and neuropathological outcomes were assessed at P20. Pups from sham-operated dams served as controls. Intranasal MSC treatment, particularly at the early postnatal treatment timepoint (P5), ameliorated key neuropathological outcomes, as evidenced by improved brain weight and cortical myelination, enhanced oligodendrocyte maturation, and dampened microglial activation compared to vehicle-treated RUPP pups. Functional impairments, measured between P13 and P56 by eye opening, grip strength, and foot faults on the tapered beam walk, showed no significant improvement. Our findings provide proof-of-concept that early-life stem cell therapy provides histological improvements in RUPP-induced brain abnormalities. Although further optimization is needed to establish whether these effects translate into functional benefits, intranasal MSCs represent a promising, minimally invasive neuroregenerative strategy with potential clinical relevance for newborns affected by chronic placental insufficiency-induced FGR.